ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

  1. Tripathy, D.
  2. Tolaney, S.M.
  3. Seidman, A.D.
  4. Anders, C.K.
  5. Ibrahim, N.
  6. Rugo, H.S.
  7. Twelves, C.
  8. Dieras, V.
  9. Müller, V.
  10. Tagliaferri, M.
  11. Hannah, A.L.
  12. Cortés, J.
Revista:
Future Oncology

ISSN: 1744-8301,  1479-6694

Ano de publicación: 2019

Volume: 15

Número: 19

Páxinas: 2211-2225

Tipo: Artigo

DOI: 10.2217/FON-2019-0180 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus